Raloxifene and cardiovascular health: Its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women

Current Pharmaceutical Design

Volumn 11, Issue 32, 2005, Pages 4187-4206

  Francucci, Cristiano Maria ^a,b   Camilletti, Andrea ^a   Boscaro, Marco ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Regionale Torrette   (Italy)

Author keywords

Atherosclerosis; Endothelial function; Hemostasis; Inflammation markers; Lipids

Indexed keywords

ANTIESTROGEN; BIOLOGICAL MARKER; CENTCHROMAN; CLOMIFENE; CONJUGATED ESTROGEN; DROLOXIFENE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHAMOXYTRIPHETOL; FULVESTRANT; GENISTEIN; GESTAGEN; IDOXIFENE; LIPID; LIPOPROTEIN; NANDROLONE DERIVATIVE; ORAL ANTIDIABETIC AGENT; PHYTOESTROGEN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE;

BONE; BREAST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEATH; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GLUCOSE METABOLISM; HEART INFARCTION; HEMOSTASIS; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; NONHUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; THROMBOSIS; UTERUS;

AGED; BINDING SITES; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE; HEMOSTASIS; HOMOCYSTEINE; HUMANS; INFLAMMATION; LIPID METABOLISM; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VENTRICULAR FUNCTION, LEFT;

EID: 27944434911     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774913237     Document Type: Review

References (238)

1. Grady D, Rubin SM, Petitti DB, Fox C, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
2. Stampfer MJ, Golditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
3. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effect of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000; 343: 522-29.
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-33.
6. Grodstein F, Stampler MJ, Manson JE, Colditz GA, Willet WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
7. Baker VL, Jaffe RB. Clinical uses of antiestrogens. Obstet Gynecol Surv 1996; 51: 45-59.
8. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res 1997; 48: 155-63.
9. Mitlak BH, Cohen FJ. Selective estrogen receptor modulators. A look ahead. Drugs 1999; 57: 653-63.
10. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain Memorial Award Lecture. Cancer Res 1990; 50: 4177-89.
11. Riggs BL. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2417-8.
12. Black LJ, Jones CD, Clark JH, Clemens JA. LY 156758: a unique antiestrogen displaying high affinity for estrogen receptors, negligible estrogenic activity and near-total estrogen antagonism in vivo. Breast Cancer Res Treat 1982; 2: 279-79.
13. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983; 32: 1031-6.
14. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-58.
15. Grese TA, Cho S, Finley DR, Godfrey AG, Jones CD, Lugar CW, et al. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 1997; 40: 146-67.
16. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997; 94: 14105-10.
17. Anzano MA, Peer CW, Smith JM, Mullen LT, Schrader MW, Logsdon DL, et al. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996; 88: 123-25,
18. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, et al. Raloxifene (LY 139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63-9.
19. Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 2003; 41(8): 331-45
20. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-83;
21. Olefsky JM. Nuclear receptor minireview series. J Biol Chem 2001; 276: 36863-64.
22. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 2000; 19: 4970-78.
23. Hall JM, McDonnell DP. The estrogen receptor-β-isoform (ER-β) of the human estrogen receptor modulates ER-α transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-78.
24. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20: 358-417.
25. Ping YI, Driscoll MD, Huang J, Bhagat S, Hilf R, Bambara RA, et al. The Effects of Estrogen-Responsive Element- and Ligand-Induced Structural Changes on the Recruitment of Cofactors and Transcriptional Responses by ER-α and ER-β. Molecular Endocrinology 2002; 16(4): 674-93.
26. Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P, Matthias P. Estrogen receptor ER-α, but not ER-β, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J Biol Chem 2001; 276(38): 35444-9.
27. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors {alpha} and {beta}. Mol Biol Cell 2004; 15(3): 1262-72.
28. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-α (ER-α) and estrogen receptor-β (ER-β) messenger ribonucleic acid in the wild-type and ER-α-knockout mouse. Endocrinology 1997; 138: 4613-21.
29. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J Comp Neurol 1997; 388: 507-25.
30. Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Lowik CW, Pols HA, et al. Differential expression of estrogen receptors-α and -β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 1997; 138: 5067-70.
31. Gustafsson JA. Estrogen receptor β a new dimension in estrogen mechanism of action. J Endocrinol 1999; 163: 379-83.
32. Witkowska HE, Carlquist M, Engstrom O, Carlsson B, Bonn T, Gustafsson JA, et al. Characterization of bacterially expressed rat estrogen receptor-β ligand binding domain by mass spectrometry: structural comparison with estrogen receptor α. Steroids 1997; 62: 621-31.
33. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 1999; 140: 800-04.
34. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-70
35. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor-β. Endocrinology 1998; 139: 4252-63.
36. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ER-α and ER-β at AP1 sites. Science 1997; 277: 1508-10.
37. Jones PS, Parrott E and White IN. Activation of transcription by estrogen receptor-α and -β is cell type- and promoter-dependent. J Biol Chem 1999; 274: 32008-14.
38. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74: 311-17.
39. Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous downregulation. Mol Endocrinol 1999; 13: 1522-34.
40. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa. B. Cell 1994; 78 (5): 773-85.
41. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996; 273: 1717-9.
42. Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AL, et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 1991; 88: 139-43.
43. Kiang, DT, Killander RE, Thomas T, Kennedy BJ. Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 1989; 49: 5312-6.
44. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999; 140: 5828-40.
45. Lonard DM, Nawaz Z, Smith CL, O'Malley. The 26S proteasome is required for estrogen receptor-α, and coactivator turnover, and for efficient estrogen receptor-α transactivation. Mol Cell 2000; 5: 939-48.
46. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-37.
47. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, et al. Estrogen receptor modulators each induce distinct conformational changes in ER-α and ER-β. Proc Natl Acad Sci USA 1999; 96: 3999-4004.
48. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, et al. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 1999; 18: 4608-4618
49. Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, et al. Estrogen receptor modulators: identification and structure-activity relationships of potent ER-α - selective tetrahydroisoquinoline ligands. J Med Chem 2003; 46(14): 2945-57.
50. Zhao C, Koide A, Abrams J, Deighton-Collins S, Martinez A, Schwartz JA, et al. Mutation of Leu-536 in human estrogen receptor-α alters the coupling between ligand binding, transcription activation, and receptor conformation. J Biol Chem 2003; 278(29): 27278-86
51. Tamrazi A, Carlson KE, Katzenellenbogen JA. Molecular sensors of estrogen receptor conformations and dynamics. Mol Endocrinol 2003; 17(12): 2593-02
52. Pike ACW, Brzozowski AM, Walton J, Hubbard RE, Thorsell A, Gustafsson JA, et al. Structural insights into the mode of action of a pure antiestrogen. Structure 2001; 9: 145-53
53. Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 1998; 10: 384-91.
54. Henttu PM, Kalkhoven E, Parker MG. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol Cell Biol 1997; 17: 1832-9.
55. Kallenberger BC, Love JD, Chatterjee VKK, Schwabe JWR A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nature Struct Biol 2003; 10: 136-40.
56. Gruber DM, Huber JC. Conjugated estrogens-the natural SERMs. Gynecol Endocrinol 1999; 13: 9-12.
57. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17-β-estradiol and raloxifene. Science 1996; 273: 1222-4.
58. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, et al. Smad4 as a transcription corepressor for estrogen receptor α. J Biol Chem 2003; 278(17): 15192-00.
59. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11: 657-66.
60. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20: 321-44.
61. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, et al. Peptide antagonists of the human estrogen receptor. Science 1999; 285: 744-46.
62. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000; 102: 753-763.
63. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465-68.
64. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995; 377: 397-04.
65. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995; 377: 454-7.
66. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999; 9: 140-7.
67. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14: 121-41.
68. Cheskis BJ, McKenna NJ, Wong CW, Wong J, Komm B, Lyttle CR, et al. Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members. J Biol Chem 2003; 278(15): 13271-7.
69. Lonard DM, Tsai SY, O'Malley BW. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol Cell Biol 2004; 24 (1): 14-24.
70. Bramlett KS, Burris TP. Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. Mol Genet Metab 2002; 76(3): 225-33.
71. Webb P, Nguyen P, Kushner PJ. Differential SERM effects on corepressor binding dictate ER-α activity in vivo. J Biol Chem 2003; 278(9): 6912-20.
72. Kauffman RE, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL, et al. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 1997; 280: 146-53.
73. Bryant HU, Magee DE, Cole HW, Chandrasechar S, Hsiung HM, Heiman ML, et al. Beneficial effects of ethynyl estradiol and raloxifene in the ovariectomized rat are dependent on an intact pituitary. J Bone Miner Res 1994; 9: suppl. 1, S135.
74. Thompson C, Hudson PM, Lucier GW. Correlation of hepatic estrogen receptor concentrations and estrogen-mediated elevation of very low density lipoproteins. Endocrinology 1983; 112: 1389-97.
75. Ma PTS, Yamamoto T, Goldstein JL, Brown MS. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17-α-ethinyl estradiol. Proc Natl Acad Sci USA 1986; 83: 792-96.
76. Bruning JC, Lingohr P, Gillette J, Hanstein B, Avci H, Krone W, et al. Estrogen receptor-alpha and Sp1 interact in the induction of the low density lipoprotein-receptor. J Steroid Biochem Mol Biol 2003; 86(2): 113-21.
77. Chao Y, Windler EE, Chen GC, Havel RJ. Hepatic catabolism of rat and human lipoproteins in rats treated with 17-α-ethinyl estradiol. J Biol Chem 1979; 254: 11360-66.
78. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83: 721-6.
79. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997; 96: 1964-9.
80. Sanjuan A, Castelo-Branco C, Colodron M, Ascaso C, Vicente JJ, Ordi J, et al. Effects of estradiol, cyproterone acetate, tibolone and raloxifene on uterus and aorta atherosclerosis in oophorectomized cholesterol-fed rabbits. Maturitas 2003; 45(1): 59-66.
81. Rahimian R, Laher I, Dube G, van Breemen C. Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J Pharmacol Exp Ther 1997; 283(1): 116-22.
82. Pavo I, Laszlo F, Morschl E, Nemcsik J, Berko A, Cox DA, et al. Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. Eur J Pharmacol 2000; 410: 101-04.
83. Rahimian R, Dube GP, Toma W, Dos Santos N, McManus BM, van Breemen C.Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 2002; 434(3): 141-9.
84. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999; 100(10): 1095-101.
85. Bracamonte MP, Rud KS, Miller VM. Mechanism of raloxifene-induced relaxation in femoral veins depends on ovarian hormonal status. J Cardiovasc Pharmacol 2002; 39(5): 704-13.
86. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by a selective estrogen receptor modulator raloxifene. Circulation 2002; 105: 1368-1373.
87. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002; 105(17): 2083-91.
88. Richardson MA, Berg DT, Calnek DS, Ciaccia AV, Joyce DE, Grinnell BW. 17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway. Endocrinology 2000; 141(10): 3908-11.
89. Zukerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 1996; 126: 65-75.
90. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 2003; 10(2): 142-46.
91. Kauffman RF, Bean JS, Fahey KJ, Cullinan GJ, Cox DA, Bensch WR. Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. J Cardiovasc Pharmacol 2000; 36: 459-65.
92. Seli E, Selam B, Mor G, Kayisli UA, Pehlivan T, Arici A. Estradiol regulates monocyte chemotactic protein-1 in human coronary artery smooth muscle cells: a mechanism for its antiatherogenic effect. Menopause 2001; 8(4): 296-01.
93. Seli E, Pehlivan T, Selam B, Garcia-Velasco JA, Arici A. Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells. Fertility and Sterility 2002; 77: 542-47.
94. Takahashi K, Ohmichi M, Yoshida M, Hisamoto K, Mabuchi S, Arimoto-Ishida E, et al. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 2003; 178(2): 319-29.
95. Mori-Abe A, Tsutsumi S, Takahashi K, Toya M, Yoshida M, Du B, et al. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 2003; 178 (3): 417-26.
96. Ogita H, Node K, Liao Y, Ishikura F, Beppu S, Asanuma H, et al. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 2004; 43(2): 237-42.
97. Ogita H, Node K, Asanuma H, Sanada S, Liao Y, Takashima S, et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardiol 2002; 40(5): 998-05.
98. Sbarouni E, Iliodromitis EK, Bofilis E, Kyriakides ZS, Kremastinos DT. Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol 2003; 467(1-3): 163-8.
99. Matthews KA, Meilanhn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641-46.
100. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
101. Ridker P, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral artery disease. JAMA 2001; 285: 2481-07.
102. Sullivan DR. Screening for cardiovascular disease with cholesterol. Clinica Chimica Acta 2002; 315: 49-60.
103. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-47.
104. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13(11): 1747-54.
105. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group 1999; 10(4): 330-6. Erratum in: Osteoporos Int 1999; 10(5): 433.
106. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19(12): 2993-00.
107. Conrad Johnston C, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Int Med 2000; 160: 3444-50.
108. De Leo V, La Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001; 184(3): 350-3.
109. Tsai KS, Yen ML, Pan HA, Wu MH, Cheng WC, Hsu SH, et al. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001; 12(12): 1020-5.
110. Nickelsen T, Creatsas G, Rechberger T, Depypere H, Erenus M, Quail D, et al. Euralox 1 Study Group. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 2001; 4(4): 320-31.
111. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. The MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 2002; 287(7): 847-57
112. Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25(3): 919-30.
113. Kung AW, Chao HT, Huang KE, Need AG, Taechakraichana N, Loh FH, et al. Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab 2003; 88(7): 3130-6.
114. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 2003; 14(10): 793-00.
115. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279(18): 1445-51.
116. Cagnacci A, Paoletti AM, Zanni A, Arangino S, Ibba G, Orrù M, et al. Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 4117-21.
117. Hokanson JE, Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk (1996); 3: 213-19.
118. Steiner G. Diabetes and atherosclerosis-a lipoprotein perspective. Diabet Med 1997; 14 (Suppl 3): S38-S44.
119. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.
120. Tilly-Kiesi M, Kahri J, Pyorala T, Puolakka J, Luotola H, Lappi M, et al. Responses of HDL subclasses, Lp(A-I) and Lp(A-I: A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Atherosclerosis 1997; 129(2): 249-59.
121. Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. Br J Obstet Gynaecol 2000; 107(3): 356-64.
122. Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 2001; 39(1): 71-7.
123. Frost PH and Have RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81(4A): 26B-31B.
124. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001; 88(12A): 9N-13N.
125. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholestcrol as a marker of coronary hearth disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153: 263-72.
126. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein-B, low apolipoproteinA-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
127. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. on behalf of the INTERHEART Study Investigators. Effect of potentially modi able risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52
128. Knopp RH. Risk factors for coronary artery disease in women. Am J Cardiol 2002; 89: 28E-34E
129. Dahlen GH, Srinivasan SR, Stenlund H, Wattigney WA, Wall S, Berenson GS. The importance of serum lipoprotein(a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States. J Intern Med 1998; 244: 417-24
130. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a) apolipoproteins A-I and B and HDL density subtractions: the atherosclerosis risk in communities (ARIC) study. Circulation 2001; 104: 1108-13
131. Scanu A. The role of lipoprotein (a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr Cardiol Rep 2001; 3: 385-90
132. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108: 111-26.
133. Sangrar W, Bajzar L, Nesheim M, Koshinsky M. Antifibrinolytic effect of recombinant lipoprotein (a) in vitro is primarily due to attenuation of t-PA-mediated Glu-plasminogen activation. Biochemistry 1995; 94: 5151-57
134. Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause 1999; 6(2): 134-7.
135. Smolders RG, Vogelvang TE, Mijatovic V, van Baal WM, Neele SJ, Netelenbos JC, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002; 41(2): 105-14.
136. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia postmenopausal women. N Engl J Med 1997; 337: 595-01.
137. Shlipak M, Simon J, Vittinghoff E, Lin F, Barrett-Connor E, Knopp R, et al. Estrogen and progestin, lipoprotein (a) and the risk of recurrent coronary heart disease after menopause. JAMA 2000; 283: 1845-52.
138. Perry W, Wiseman R. Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women. Effects on lipids, coagulation factors, haematology and biochemistry. Maturitas 2002; 42: 157-64.
139. Snyder ML, Hay RV, Whitington PF, Scanu AM, Fless GM. Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes. Comparison with cultured human monocyte-macrophages and fibroblasts. Arterioscler Thromb 1994; 14(5): 770-9.
140. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998; 158: 617-21.
141. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspectives from the Framingham study. Am Heart J 1987; 114: 413-29.
142. Barrett-Conner E, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991; 265: 627-31.
143. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-45.
144. Palin SL, Kumar S, Sturdee DW, Barnett AH. HRT in women with diabetes - review of the effects on glucose and lipid metabolism. Diabetes Res Clin Pract 2001; 54(2): 67-77
145. Andersson B, Johannsson G, Holm G, Bengtsson B, Sashegyi A, Pavo I, et al. Raloxifene Does Not Affect Insulin Sensitivity or Glycemic Control in Postmenopausal Women with Type 2 Diabetes Mellitus: A Randomized Clinical Trial. J Clin Endocrinol Metab 2002; 87(1): 122-28.
146. Lee CC, Kasa-Vubu JZ and Supiano MA. Differential Effects of Raloxifene and Estrogen on Insulin Sensitivity in Postmenopausal Women. JAGS 2003; 51: 683-88.
147. Cucinelli F, Soranna L, Romualdi D, Muzj G, Mancuso S and Lanzone A. The Effect of Raloxifene on Glyco-Insulinemic Homeostasis in Healthy Postmenopausal Women: A Randomized Placebo-Controlled Study. J Clin Endocrinol Metab 2002; 87(9): 4186-92.
148. Ferrari P, Alleman Y, Shaw S, Riesen W, Weidmann P. Reproducibility of insulin sensitivity by the minimal model method. Diabetologia 1991; 34: 527-30.
149. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79: 790-00.
150. Haffner SM, Valdez RA, Morales PA, Hazuda HP, Stern MP. Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 1993; 77: 56-60.
151. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM, 12- yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991; 40: 123-28.
152. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interlukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999; 104: 246-57.
153. Mijatovic V, van der Mooren MJ, Stehouwwer CD, Netelenbos JC, Kenemans P. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol 1999; 13: 130-44.
154. Taubes G. Cardiovascular disease: does inflammation cut to the heart of the matter? Science 2002; 296: 242-45.
155. Ridker PM High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-18.
156. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 1999; 101: 2149-53.
157. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma
158. Baumann H, Gauldie J. The acute phase response. Immunol Today 1999; 15: 74-80.
159. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-Reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
160. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996; 157: 473-79.
161. Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis 1997; 132: 131-38.
162. Galve-de Rochemonteix B, Wiktorowicz K, Kushner I, Dayer JM. C-Reactive protein increases production of IL-1α IL-1β, and TNF-α, and expression of mRNA by human alveolar macrophages. J Leukocyte Biol 1993; 53: 439-45.
163. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14.
164. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women. The Women's Health and Ageing Study. Circulation 2001; 103: 947-53.
165. Schumacher A, Seljeflot I, Sommervoll L, Christensen B, Otterstad JE, Arnesen H. Increased levels of markers of vascular inflammation in patients with coronary heart disease. Scand J Clin Lab Invest 2002; 62: 59-68.
166. Mantovani A, Sozzani S, Introna M. Endothelial activation by cytokines. Ann NY Acad Sci 1997; 832: 93-16.
167. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled study. J Clin Endocrinol Metab 2000; 85: 214-18.
168. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88: 825-28.
169. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1999; 11: 1043-51.
170. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1999; 65: 297-02.
171. Graham I, Daly L, Refsum H, Robinson K, Brattstrom L. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-81.
172. Cattaneo M. Hyperhomocysteinaemia and atherothrombosis. Lipids 2001; 36(Suppl 1): 13-26.
173. Ridker P, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281: 1817-21.
174. Hirsch S, de la Maza P, Mendoza L, Peterman M, Glasinovic A, Paulinelli P, et al. Endothelial function in healthy younger and older hyperhomocysteinemic subjects. J Am Geriatr Soc 2002. 50: 1019-23.
175. Hak AE, Polderman KH, Westendorp IC, Jakobs C, Hofman A, Witteman JC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000; 149: 163-68.
176. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998; 70: 1085-89.
177. Yildirir A, Aybar F, Tokgozoglu L, Yarali H, Kabakci G, Bukulmez O, et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest 2002; 53: 54-58.
178. Madsen JS, Kristensen SR, Klitgaard NA, Bladbjerg EM, Abrahamsen B, Stilgren L, et al. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. Am J Obstet Gynecol 2002; 187: 33-39.
179. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and the risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-/5.
180. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Brit J Haematol 1990; 74: 77-81.
181. Scarabin PY, Vissac AM, Kirzin JM, Bourgeat P, Amiral J, Agher R, et al. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996; 16(9): 1170-76.
182. Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pillusing, and menopause. Thromb Haemost 1985; 54: 475-79.
183. Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995; 16(suppl A): 21-24.
184. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70: 584-87.
185. Hoibraten E, Abdelnoor M, Morten Dandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism. Thromb Haemost 1999; 82: 1218-21.
186. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
187. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsoupoulos D, Liang Y-L, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404-9.
188. Reiner A.P, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-95.
189. Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen: Its relationship with oral contraception, the menopause, and hormone replacement therapy. Clin Biochem 1992; 25: 403-5.
190. De Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis Thromb Vasc Biol 1996; 121: 185-91.
191. Vasse M, Collet JP, Soria J, Mirshahi SS, Vanmight JP, Soria C. Fibrinogen, a vascular factor: A simple marker or a real cause of vascular lesion? Thromb Res 1994; 75: 349-52.
192. Vasse M, Paysant J, Soria J, Collet JP, Vannier JP, Soria C. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis 1996; 26 (Suppl 4): 331-39.
193. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003; 42 (4): 698-04.
194. Dahlhack B. Blood coagulation. Lancet 2000; 335: 1627-32.
195. Juhan-Vague L, Alessi MC. Plasminogen activator inihibitor and atherothrombosis. Thromb Haemost 1993; 70: 138-43.
196. Lopez Y, Paloma MJ, Rifon J, Cuesta B, Paramo JA. Measurement of prothrombic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999; 93: 71-78.
197. Kon Koh K, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90.
198. Kroon U, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostatic variables. Thromb Haemost 1994; 71: 420-23.
199. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-78.
200. McGorisk GM, Trasure CB. Endothelial dysfunction in coronary heart disease. Curr Opin Cardiol 1996; 11: 341-50.
201. Celermajer DS. Endothelial dysfunction: does it matter? is it reversible? J Am Coll Cardiol 1997; 30: 325-53.
202. Cayette AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14: 753-59.
203. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
204. Ylikorkala O, Orpana A, Puolakka J, Pyorala T, Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinoi Metab 1995; 80: 3384-87.
205. Dubey RK. Vasodilator-derived nitric oxide inhibits fetal calf serum and angiotensin-II-induced growth of renal arteriolar smooth muscle cells. J Pharmacol Exp Ther 1994; 269: 402-08.
206. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-32.
207. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc1996; 71: 769-77.
208. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 587-90.
209. Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet 1975; 1: 30.
210. Lufkin EG, Fass DN, O'Fallon WM, Bowie EJ. Increased von Willebrand factor in diabetes mellitus. Metabolism 1979; 28: 63-66.
211. Ruggeri ZM. Cell adhesion in vascular biology: von Willebrand Factor. J Clin Invest 1997; 99: 559-64.
212. Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, et al. Randomized, double blind, placebo-controllcd study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-9.
213. Duschek EJ, Stehouwer CD, de Valk-de Roo GW, Schalkwijk CG, Lambert J, Netelenbos C. Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women. J Int Med 2003; 254: 85-94.
214. van Kesteren PJ, Kooistra T, Lansink M, van Kamp GJ, Asscheman H, Gooren LJ, et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79: 1029-33.
215. van Baal WM, Kenemans P, Emeis JJ, Schalkwijk CG, Mijatovic V, van der Mooren MJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71: 663-70.
216. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111-18.
217. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247-53.
218. Cerquetani E, Mercuro G, Fini M, Zoncu S, Onorati D, Vitale C, et al. Hormone replacement therapy but not raloxifene improves endothelial function in postmenopausal women with increased cardiovascular risk. Menopause 2001; 8: 453.
219. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial Function and Menopause: Effects of Raloxifene Administration. J Clin Endocrinol Metab 2003; 88(5): 2135-40.
220. Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 2003; 304-09.
221. Cagnacci A, Arangino S, Renzi A, Zanni AL, and Volpe A. Raloxifene does not influence flow-mediated endotheliumdependent and endothelium-independent vasodilatation of osteopenic postmenopausal women Am J Obstet Gynecol 2003; 188: 313-17.
222. Ceresini G, Marchini L, Rebecchi I, Morganti S, Bertone L, Montanari I, et al. Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis 2003; 167: 121-27.
223. Post MS, van der Mooren J, van Baal WM, Neele SJM, Netelenbos JC, Kenemans P. Raloxifene reduces impedance to flow within uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study. Am J Obstet Gynecol 2001; 185: 557-62.
224. Maulik D. Principles of Doppler signal processing and haemodynamic analysis. In: J.A. Copel and K.L. Reed, Editors, Doppler Ultrasound in Obstetrics and Gynecology, Raven, New York 1995; 1-18.
225. Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal estradiol and time since menopause. Lancet 1991; 338: 839-42.
226. Naessen T, Bakos O. Carotid vascular resistance in long-term estrogen users. Obstet Gynecol 2001; 97: 327-32.
227. Setacci C, La Marca A, Agricola E, Morgante G, Setacci F, Cappelli A, et al. Effects of the selective estrogen receptor modulator, raloxifene, on carotid artery pulsatility index in postmenopausal women. Am J Obstet Gynecol 2002; 186(4): 832-35.
228. Vogelvang TE, Mijatovic V, Kamp O, Netelenbos JC, Neele SJM, Pines A, et al. Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: Two randomized, placebo-controlled, 2-year studies. Am J Obstet Gynecol 2002; 186: 729-36.
229. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002; 105: 933-38.
230. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: a role of superoxide dismutase. Circulation 2001; 103: 799-05.
231. Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, et al. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol 2001; 88: 392-95,
232. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-57.
233. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281(23): 2189-97
234. Evista (raloxifene) tablets product monograph. Indianapolis: Eli Lilly & Co.; 1997.
235. Delmas PD, Mitlak BH, Christiansen C. Effects of raloxifene in postmenopausal women. N Engl J Med 1998; 338: 1313-4.
236. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Design 2004; 10(2): 203-11.
237. Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures. Curr Pharm Design 2003; 9(29): 2417-23.
238. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Design 2004; 10(22): 2779-86.